<DOC>
	<DOCNO>NCT01127269</DOCNO>
	<brief_summary>Primary Objective : Percentage patient achieve Glycosylated Hemoglobin ( HbA1c ) &lt; 7 % severe nocturnal hypoglycemic episode 6 month Secondary Objectives : - Glycosylated Hemoglobin ( HbA1c ) change baseline 6 month - Insulin glargine dose 3 6 month - Hypoglycemic episode ( type )</brief_summary>
	<brief_title>Safety Effectiveness Study Insulin Glargine ( LANTUS ) Initiation Titration Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Patients diagnosis type 2 diabetes 6 month Patients treat Oral AntiDiabetics ( OADs monotherapy combination ) HbA1c &gt; 7 % &lt; 10 % and/or treat NPH insulin HbA1c &gt; 7 % &lt; 10 % treat NPH insulin experience severe and/or nocturnal hypoglycemia last 6 month . Ability perform SMBS insulin selftitration physician guidance . Body Mass Index ( BMI ) &gt; 21 kg/ m2 . Signature informed consent . Exclusion criterion : Hospitalized patient . Pregnant woman intention become pregnant . Unexplained weight loss 10 % last 6 month . Women child bear potential use effective contraceptive method . Women breast feeding period . Patients chronic treatment systemic corticosteroid protease inhibitor . History drug alcohol abuse . Diabetic retinopathy surgical treatment 3 month previous study entry patient could require surgical treatment follow 6 month study entry . Major systemic disease clinically important would interfere implementation interpretation study , discretion investigator . Renal failure know creatinine &gt; 1.4 mg/dl woman &gt; 1.5 mg/dl men . Known hypersensitivity glargine excipients . Patients history hospitalization due cardiovascular event , cardiovascular procedure past 6 month . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>